Page 16 - GPD-3-4

Gene & Protein in Disease Human sirtuins (SIRT1-7) in cancer

that resveratrol, a sirtuin activator, has a cytotoxic effect Ethics approval and consent to participate
and causes cell cycle arrest and inhibition of mitochondrial
respiration in breast cancer cell lines mediated by SIRT1 Not applicable.
and 3. Synthetic SIRT1 activators SRT1720 and SRT2104 Consent for publication
119
exert antiproliferative effects on cancer cells 120,121 and assist
with the prevention of chemotherapy resistance. 122,123 Not applicable.
Sirtuin inhibitors, such as cambinol and tenovins, are also Availability of data
being studied as potential therapeutic agents that induce
apoptosis of cancer cells with defective p53 pathways and Not applicable.
restore sensitization to chemotherapy. 124,125 The integration
of sirtuin modulators in cancer treatment regimens could References
complement existing therapies, offering a more tailored 1. Yamamoto H, Schoonjans K, Auwerx J. Sirtuin functions in
and effective approach. 126 health and disease. Mol Endocrinol. 2007;21:1745-1755.
5. Conclusion doi: 10.1210/me.2007-0079
2. Feldman JL, Dittenhafer-Reed KE, Denu JM. Sirtuin catalysis
Sirtuins play a pivotal role in maintaining cellular and regulation. J Biol Chem. 2012;287:42419-42427.
homeostasis and normal physiological functions. Altered
metabolism and genomic instability are hallmark features doi: 10.1074/jbc.R112.378877
of different types of cancer. Dysregulated expression 3. Haigis MC, Sinclair DA. Mammalian sirtuins: Biological insights
patterns of different classes of mammalian sirtuins have and disease relevance. Annu Rev Pathol. 2010;5:253-295.
been observed in tumor cells. Dysregulated sirtuins play doi: 10.1146/annurev.pathol.4.110807.092250
a dual role in cancer, exhibiting both tumor-suppressive
and oncogenic activities, often maintaining a delicate 4. Bonkowski MS, Sinclair DA. Slowing ageing by design: The
rise of NAD and sirtuin-activating compounds. Nat Rev Mol
balance between the two. Understanding the fundamental Cell Biol. 2016;17:679-690.
mechanisms and conditions that dictate their divergent
roles in cancer holds significant promise for sirtuins as doi: 10.1038/nrm.2016.93
therapeutic targets and potential biomarkers for cancer 5. Watroba M, Szukiewicz D. Sirtuins at the service of healthy
diagnosis and prognosis. Future research could delve longevity. Front Physiol. 2021;12:724506.
deeper into elucidating the intricate molecular pathways doi: 10.3389/fphys.2021.724506
underlying the dual nature of sirtuins in cancer, exploring
novel therapeutic interventions that target specific sirtuin 6. Blander G, Guarente L. The Sir2 family of protein
deacetylases. Annu Rev Biochem. 2004;73:417-435.
isoforms, and investigating their utility as predictive and
prognostic markers in cancer management. doi: 10.1146/annurev.biochem.73.011303.073651
7. Michishita E, Park JY, Burneskis JM, Barrett JC, Horikawa I.
Acknowledgments Evolutionarily conserved and nonconserved cellular
None. localizations and functions of human SIRT proteins. Mol
Biol Cell. 2005;16;4623-4635.
Funding doi: 10.1091/mbc.e05-01-0033
This work was supported by VEGA grant no. 1/0622/20 of 8. Carafa V, Rotili D, Forgione M, et al. Sirtuin functions and
the Scientific Grant Agency of the Ministry of Education, modulation: From chemistry to the clinic. Clin Epigenetics.
Research and Sport of the Slovak Republic, and VVGS 2016;8:61.
grant no. VVGS – 2022-2199. doi: 10.1186/s13148-016-0224-3
Conflict of interest 9. Yang Y, Liu Y, Wang Y, et al. Regulation of SIRT1 and its
roles in inflammation. Front Immunol. 2022;13:831168.
The authors declare that they have no competing interests.
doi: 10.3389/fimmu.2022.831168
Author contributions 10. Lu C, Zhao H, Liu Y, et al. Novel role of the SIRT1 in endocrine
and metabolic diseases. Int J Biol Sci. 2023;19(2):484-501.
Conceptualization: Daniela Szabóová, Roman Beňačka
Writing–original draft: All authors doi: 10.7150/ijbs.78654
Writing–review & editing: Zuzana Guľašová, Zdenka 11. Lu W, Ji H, Wu D. SIRT2 plays complex roles in
Hertelyová neuroinflammation neuroimmunology-associated disorders.

Volume 3 Issue 4 (2024) 8 doi: 10.36922/gpd.4100